Stryker Corporation (NYSE:SYK) Receives $432.24 Consensus PT from Analysts

Shares of Stryker Corporation (NYSE:SYK) have earned a consensus rating of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $432.2381.

Several analysts recently commented on the stock. UBS Group set a $408.00 price target on shares of Stryker in a research report on Monday, October 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Needham & Company LLC boosted their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Wells Fargo & Company boosted their price objective on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Finally, Barclays boosted their price objective on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd.

Stryker Stock Up 0.5%

Shares of NYSE:SYK opened at $383.56 on Friday. The company has a market capitalization of $146.64 billion, a PE ratio of 50.80, a P/E/G ratio of 2.75 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker has a twelve month low of $329.16 and a twelve month high of $406.19. The firm has a 50 day simple moving average of $379.87 and a 200-day simple moving average of $380.29.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the prior year, the firm earned $2.81 EPS. Stryker’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities analysts predict that Stryker will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Stephens Inc. AR grew its stake in shares of Stryker by 2.7% during the 3rd quarter. Stephens Inc. AR now owns 13,048 shares of the medical technology company’s stock worth $4,824,000 after purchasing an additional 338 shares during the period. Cullinan Associates Inc. grew its stake in Stryker by 0.6% in the 3rd quarter. Cullinan Associates Inc. now owns 8,195 shares of the medical technology company’s stock valued at $3,029,000 after acquiring an additional 50 shares during the last quarter. Ashton Thomas Securities LLC grew its stake in Stryker by 6.6% in the 3rd quarter. Ashton Thomas Securities LLC now owns 1,310 shares of the medical technology company’s stock valued at $482,000 after acquiring an additional 81 shares during the last quarter. LVZ Inc. grew its stake in Stryker by 7.4% in the 3rd quarter. LVZ Inc. now owns 4,726 shares of the medical technology company’s stock valued at $1,747,000 after acquiring an additional 327 shares during the last quarter. Finally, Arcadia Investment Management Corp MI grew its stake in Stryker by 0.3% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 67,655 shares of the medical technology company’s stock valued at $25,010,000 after acquiring an additional 209 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.